| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/19/2007 | US20070087044 Transdermal Method and Patch for Emesis |
| 04/19/2007 | US20070087043 Nicotine transdermal preparation and production method thereof |
| 04/19/2007 | US20070087041 Waterless Lotion and Lotion-Treated Substrate |
| 04/19/2007 | US20070087040 Oil cleaning sheets for makeup |
| 04/19/2007 | US20070087027 Extremely small size of electrospun fibers, and the resulting interstices therebetween, provides an effective vehicle for drug and radiation delivery, and forms an effective membrane for use in fuel cells |
| 04/19/2007 | US20070087025 Reiteratively layered medical devices and method of preparing same |
| 04/19/2007 | US20070087022 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| 04/19/2007 | US20070086986 Preparation of three-dimensional mammalian ovarian follicular cell and ovarin follicle culture systems in a biocompatible matrix |
| 04/19/2007 | US20070086982 Gene therapy for regulating smooth muscle tone |
| 04/19/2007 | US20070086978 Colon cleansing compositions and methods |
| 04/19/2007 | US20070086961 Tooth whitening substances |
| 04/19/2007 | US20070086958 Formation of medically useful gels comprising microporous particles and methods of use |
| 04/19/2007 | US20070086957 Combination of medicaments for the treatment of respiratory diseases |
| 04/19/2007 | US20070086956 Method for accelerating the rate of mucociliary clearance |
| 04/19/2007 | US20070086955 Form of administration for controlling primary headaches |
| 04/19/2007 | US20070086953 Medicinal Aerosol Formulation Products With Improved Chemical Stability |
| 04/19/2007 | US20070086952 Rapid Acting and Prolonged Acting Inhalable Insulin Preparations |
| 04/19/2007 | US20070086951 Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments |
| 04/19/2007 | DE202006018367U1 CGM Medizinische Textilie CGM Medical textile |
| 04/19/2007 | DE102005049315A1 Granulate material, useful to fill the defective implants, comprises polymorphene, where the entire side of the polymorphene is provided with spherical granulate and a basic scaffolding as a cavity |
| 04/19/2007 | CA2625804A1 Pharmaceutical composition based on a morpholinic antimycotic agent and a water-soluble film-forming agent for ungual and periungual application |
| 04/19/2007 | CA2625620A1 Chitosan and heparin nanoparticles |
| 04/19/2007 | CA2625568A1 Ophthalmic emulsions containing prostaglandins |
| 04/19/2007 | CA2625557A1 Stable, durable granules with active agents |
| 04/19/2007 | CA2625532A1 Agent for applying to mucosa containing a hydrophobic group binding type glycosaminoglycan |
| 04/19/2007 | CA2625042A1 Iontophoretic preparation for treatment of breast cancer and/or mastitis |
| 04/19/2007 | CA2624910A1 Biocompatible block copolymer, use thereof, and production method thereof |
| 04/19/2007 | CA2624845A1 A composition for the treatment of diabetic periodontitis |
| 04/19/2007 | CA2624838A1 Retard formulation for pralnacasan |
| 04/19/2007 | CA2624786A1 Aerosol formulation for the inhalation of beta agonists |
| 04/19/2007 | CA2624512A1 Fiber satiety compositions |
| 04/19/2007 | CA2623749A1 Reduction of saltiness with sweeteners |
| 04/19/2007 | CA2623542A1 Methods of preparing polymers having terminal amine groups using protected amine salts |
| 04/19/2007 | CA2622464A1 Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment |
| 04/19/2007 | CA2622342A1 Processing of chitosan and chitosan derivatives |
| 04/18/2007 | EP1775305A2 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent |
| 04/18/2007 | EP1774989A2 Treatment of cancer with high intensity focused ultrasound and chemotherapy |
| 04/18/2007 | EP1774978A1 Application of hyaluronic acid to sentinel lymph node identification |
| 04/18/2007 | EP1774975A1 Use of human lysozyme in preparation of medicine for treating acne |
| 04/18/2007 | EP1774971A1 Chitosan and heparin nanoparticles |
| 04/18/2007 | EP1774969A2 Controlled release oxycodone compositions |
| 04/18/2007 | EP1774967A1 Solid oral dosage forms comprising valsartan |
| 04/18/2007 | EP1774964A1 Nicotine transdermal preparation and production method thereof |
| 04/18/2007 | EP1774963A1 Galactogenic compositions based on silymarin |
| 04/18/2007 | EP1774962A1 Lipid carrier and method of preparing the same |
| 04/18/2007 | EP1774961A2 Methods for stabilizing ophthalmic compositions |
| 04/18/2007 | EP1774858A1 Nutritional compositions based on amino acids |
| 04/18/2007 | EP1773988A2 Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| 04/18/2007 | EP1773936A2 Unagglomerated core/shell nanocomposite particles |
| 04/18/2007 | EP1773914A1 Polyamino acids functionalised by hydrophobic grafts bearing an anionic charge and applications thereof, such as therapeutic applications |
| 04/18/2007 | EP1773453A2 Acidic solid oral compositions without erosive potential in saliva and method for determining erosive potential in saliva |
| 04/18/2007 | EP1773452A2 Lysis / resealing process and device for incorporating an active ingredient in erythrocytes |
| 04/18/2007 | EP1773450A2 Therapeutically combinations |
| 04/18/2007 | EP1773410A2 Device for releasing an active ingredient and piece of jewelry embodied to give off a scent |
| 04/18/2007 | EP1773399A1 Hydrogels of hyaluronic acid and alpha, beta-polyaspartylhydrazide and their biomedical and pharmaceutical uses |
| 04/18/2007 | EP1773369A1 Pharmaceutical compositions and methods for peptide treatment |
| 04/18/2007 | EP1773363A1 Ngna compositions and methods of use |
| 04/18/2007 | EP1773358A2 Biomaterial |
| 04/18/2007 | EP1773353A2 Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones |
| 04/18/2007 | EP1773350A2 Opthalmic compositions and methods for treating ophthalmic conditions |
| 04/18/2007 | EP1773335A2 Nanoparticle dispersion containing lactam compound |
| 04/18/2007 | EP1773311A1 A gastric retained dosage form of gabapentin |
| 04/18/2007 | EP1773303A2 Self-assembling nanoparticle drug delivery system |
| 04/18/2007 | EP1773302A1 Rapidly disintegrating gelatinous coated tablets |
| 04/18/2007 | EP1773301A2 Compositions comprising amphotericinb methods and systems |
| 04/18/2007 | EP1773300A2 Solid pharmaceutical composition comprising mirtazapine |
| 04/18/2007 | EP1773299A2 Tissue matrix system |
| 04/18/2007 | EP1773298A1 Multiple layered liposome and preparation method thereof |
| 04/18/2007 | EP1773297A1 Infusion and injection solution of levodopa |
| 04/18/2007 | EP1773296A2 Topical antiviral formulations |
| 04/18/2007 | EP1773294A2 Compositions for delivering highly water soluble drugs |
| 04/18/2007 | EP1773293A2 Compositions and methods for treating central precocious puberty |
| 04/18/2007 | EP1773292A1 Rapidly disintegrating orodispersible composition containing nonfilamentous coprocessed polyols particles and silicified microcrystalline cellulose |
| 04/18/2007 | EP1773291A2 Bifunctional bioadhesive compositions for oral implantology |
| 04/18/2007 | EP1773265A2 Nano-particle production |
| 04/18/2007 | EP1773253A2 Spinal disc nucleus pulposus implant |
| 04/18/2007 | EP1773240A2 Silk-based drug delivery system |
| 04/18/2007 | EP1773135A1 Completely-soluble solid particle(s) based on dietary fibres |
| 04/18/2007 | EP1677777B1 Pellets containing venlafaxine hydrochloride |
| 04/18/2007 | EP1633369B1 Process to minimize loss through adhesion to equipment surfaces |
| 04/18/2007 | EP1572190B1 Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof |
| 04/18/2007 | EP1556061B1 Photokinetic delivery of biologically active substances using pulsed incoherent light |
| 04/18/2007 | EP1500029B1 Infusion therapy flow rate adjustment system and method |
| 04/18/2007 | EP1480636B1 Self emulsifying drug delivery systems for taxoids |
| 04/18/2007 | EP1478350B1 Pharmaceutical dosage forms comprising tablet core having a tensile strength below 38 n/sqcm and a coating to protect the soft core |
| 04/18/2007 | EP1453545B1 Water-soluble polymer conjugates of retinoic acid |
| 04/18/2007 | EP1432406B1 Pharmaceutical composition comprising a water/oil/water double microemulsion incorporated in a solid support |
| 04/18/2007 | EP1401479B1 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 04/18/2007 | EP1372602B1 Flexible microchip devices for ophthalmic and other applications |
| 04/18/2007 | EP1361862B1 Liposome-mediated dna administration |
| 04/18/2007 | EP1317257B1 Plaster |
| 04/18/2007 | EP1283720B1 Recombinant or purified polyclonal antibodies for treating allergy |
| 04/18/2007 | EP1227812B1 Topical nasal treatment using desloratadine and mometasone furoate |
| 04/18/2007 | EP1201232B1 Patches for external use |
| 04/18/2007 | EP1180368B1 Freeze dried hgf preparations |
| 04/18/2007 | EP1037622B1 Taurine derivatives usable in the treatment of retinal disorders |
| 04/18/2007 | EP1017390B1 Coated tablet comprising nicotinic acid or a compound metabolized to nicotinic acid in an extended release form, and a coating containing an hmg-coa reductase inhibitor in an immediate release form |
| 04/18/2007 | EP1007080B1 Formulation for the sustained release of peptide agonists and analogues of GnRH |
| 04/18/2007 | EP1005374B1 Microparticles for delivery of nucleic acid |
| 04/18/2007 | CN1950474A Adhesive for dermal patch and production process thereof |